Skip to main content
. 2011 Feb 25;2(3):449–455. doi: 10.3892/etm.2011.218

Figure 1.

Figure 1.

MO17974 trial: erlotinib, at escalating doses, administered orally from day 3 to day 10, was combined with FOLFOX4 administered every 14 days. ML18511 trial: erlotinib, at escalating doses, was administered on days 2–18 of each 21-day cycle combined with XELOX plus bevacizumab. qd, once a day; bid, twice a day.